clinical-trials-2019-scientifictracks

4 / 4

allied
academies
Page 48
Notes:
September 23-24, 2019 | Prague, Czech Republic
2nd International Conference on
Palliative Care
Clinical Trials and Pharmacovigilance
Joint Event
&
Do we need pharmacovigilance of drugs like Metformin?
E Sumbul Khalid, A Sadaf Moeez, B Sania Shaheen, C Madiha Khalid and D Zoya Khalid
International Islamic University, Pakistan
Diabetes Mellitus is an overwhelming medical crisis for
Pakistan (ranked 6th globally) with an expected 14.5
million patients by 2025. Type 2 Diabetes Mellitus (T2DM)
predominates, with around 90%, of all the reported diabetic
cases in Pakistan. Metformin (Glucophage) is the go-to, first
line drug monotherapy against Type 2 Diabetes Mellitus
around the world. A global observation is that in spite of
the drug's proper usage, around 35% of T2DM individuals
do not succeed to achieve initial optimum glycemic control
by metformin monotherapy. In this era of personalized
medication, it has been established that genetic factors are
responsible for 64% to 94% of variations in an individual for
renal clearance of any specific drug, including metformin.
We conducted a study to estimate the contribution of
genotypic differences among diabetics for their individual
reponses to metformin affects. Many SNPs from the genes
associated with metformin pharmacokinetics were found
associated with these differences. The analysed genes were
SLC22A1, SLC22A2, SLC22A3, SLC47A1 and SLC47A2. We
report strong, statistically significant, associations of certain
SNPs with ineffectiveness of metformin in non-responding
patients.
Assessment of individual responses (or no responses) of
patients to their prescribed drugs come under the umbrella
of 'Pharmacovigilance' and it is recommended that medical
practitioners all over the world, but particularly in Pakistan,
may consider genotypic evaluation of their patients before
prescribing metformin to all the patients, since a good (35%)
patients do not respond to metformin.
Speaker Biography
ESumbulKhalidcompletedherPhDfromPMAS-AridAgricultureUniversity,
Rawalpindi, Pakistan. She has been serving in the Department of Biological
Sciences,InternationalIslamicUniversity,Islamabad,Pakistan,campussince
2010. She has published more than 20 papers in reputed journals that has
been cited more than 40 times. Her research interest includes diagnostics
and therapeutics, pharmacogenomics, oncogenic cellular pathways.
She is also serving as an editorial board member of reputed journals.
e:
Journal of Clinical Research and Pharmacy | Volume 2
J Clin Res Pharm, Volume:2